,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,dividendRate,dividendYield,exDividendDate,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Mr. Pierre  Mottet', 'age': 60, 'title': 'Chairman of The Board', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 52500, 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
1,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Mr. Olivier  Legrain', 'age': 54, 'title': 'CEO, Pres, MD & Exec. Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 880004, 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
2,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Mr. Yves  Jongen', 'age': 75, 'title': 'Founder, Chief Research Officer, MD & Exec. Director', 'yearBorn': 1947, 'fiscalYear': 2022, 'totalPay': 576920, 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
3,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Ms. Soumya  Chandramouli', 'age': 43, 'title': 'Chief Financial Officer', 'yearBorn': 1979, 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
4,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Mr. Frederic  Nolf', 'age': 49, 'title': 'Chief HR & Sustainability Officer', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
5,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Marc  Van der Burght', 'title': 'Chief Operation Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
6,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Olivier  Lechien', 'title': 'Corp. Communication Director', 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
7,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Thomas  Canon', 'title': 'Sustainability Program Director', 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
8,"3, Chemin du Cyclotron",Louvain-la-Neuve,1348,Belgium,32 1 047 58 11,32 1 047 58 10,https://www.iba-worldwide.com,Medical Devices,Healthcare,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",2000,"{'maxAge': 1, 'name': 'Bruno  Scutnaire', 'title': 'Pres of IBA RadioPharma Solutions', 'exercisedValue': 0, 'unexercisedValue': 0}",2,8,7,10,8,1693526400,1672444800,86400,2,10.28,10.5,10.04,10.6,10.28,10.5,10.04,10.6,0.21,0.020399999,1687996800,0.784909,14.911765,66087,66087,34966,53515,53515,0.0,0.0,0,0,350640192,9.81,18.66,0.94599897,13.0984,15.6079,0.21,0.020428015,EUR,233427488,-0.05258,21148954,29171400,0.29134,0.27519,3.983,2.5458198,1672444800,1703980800,1688083200,-19489000,-0.67,0.68,0.63,-24.538,BRU,EQUITY,IBAB.BR,IBAB.BR,ION BEAM APPLICATIONS,Ion Beam Applications SA,946972800,Europe/Brussels,CEST,7200000,10.14,18.0,18.0,18.0,18.0,1.5,strong_buy,1,103311000,3.549,-9513000,41584000,0.611,1.01,370656000,47.85,12.396,-0.014529999,-0.21166,-61654624,-47176000,0.059,0.29468,-0.02567,-0.03639,EUR,
